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Received March 3, 2014; accepted July 3, 2014AbstractDisease affecting the cornea is a common cause of blindness worldwide. To date, the amniotic membrane (AM) is the most widely used
clinical method for cornea regeneration. However, donor-dependent differences in the AM may result in variable clinical outcomes. To overcome
this issue, biomaterials are currently under investigation for corneal regeneration in vitro and in vivo. In this article, we highlight the recent
advances in hydrogels, bioengineered prosthetic devices, contact lenses, and drug delivery systems for corneal regeneration. In clinical studies,
the therapeutic effects of biomaterials, including fibrin and collagen-based hydrogels and silicone contact lenses, have been demonstrated in
damaged cornea. The combination of cells and biomaterials may provide potential treatment in corneal wound healing in the future.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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As a sense organ of light perception, the ocular surface is
the outermost part of the eyes, interacting with the outside
environment during most of the daytime and protecting the
intraocular tissues. The ocular surface is guarded by the eyelid
when the eye is closed and comprises transparent cornea
centrally with surrounding conjunctival tissues. The conjunc-
tiva is mainly composed of bulbar, palpebral conjunctiva to
cover the sclera and the tarsus. The conjunctiva reflects to
form a fornix on three sides and a semilunar fold medially.Conflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical AssThe epithelium of the conjunctiva is continuous with the
cornea at the limbus, where it is viewed as the major niche of
corneal stem cells for regeneration of epithelial cells.1e3 The
cornea is the most vital refractive medium in the anterior part
of the eye, and it is responsible for two-thirds of the total
ocular refractive power. From the outer surface to the inner-
most cellular layer, the cornea consists of the epithelium,
Bowman's layer, stroma, Descemet's membrane, and
endothelium.4
Ocular surface diseases may be induced by extrinsic in-
fectious pathogens, chemical burn, an intrinsic autoimmune
reaction, dysregulation of the tear film, and corneal decom-
pensation. A disrupted ocular surface not only leads to severe
irritation but also can result in severe visual loss. Here, we
introduce some important diseases of the ocular surface and
the cornea.
Infectious corneal diseases are mainly derived from bac-
teria, fungi, viruses, and other rare pathogen invaginations,ociation. All rights reserved.
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treatment, the complications that follow corneal infection,
such as scar formation, corneal thinning, and corneal decom-
pensation, may require surgical intervention in order to restore
vision. Penetrating keratoplasty, partial layer corneal graft
(lamellar keratoplasty), or endothelial keratoplasty can be
performed, depending on which part of the cornea tissue is
damaged.7e9
Chemical injury to the eye may range from mild irritation
to complete destruction of the ocular surface and even loss of
the eye. Depending on the offending agent, chemical injury
can be divided into acidic or alkaline damage, which have
different consequences. When acid come in contact with the
eye, the proteins of the conjunctival and corneal tissues will
become denatured and precipitated to prevent further intra-
ocular penetration of chemical agents. Thus, it will localize
the damage in the superficial layer. By contrast, strong alkalis
will cause saponification of fatty acids in the cell membrane
and result in cellular disruption. They easily penetrate the
corneal stroma and rapidly destroy the proteoglycan ground
substance and collagen fibers of the matrix. They may also
infiltrate the anterior chamber and induce intense intraocular
inflammation and tissue destruction. Both acid and alkaline
injury to the ocular surface will possibly cause severe tissue
necrosis and inflammation. The extensive conjunctival and
corneal limbal epithelial damage will result in poor epithelial
healing, neovascularization, scar formation, and fornix
shortage. The management of complications after chemical
injury aims to restore the normal physiological condition of
the ocular surface and vision. Several methods can be per-
formed in the reconstruction of the ocular surface, including
autologous conjunctival transplantation, limbal stem cell
transplantation (LSCT), autologous cultivated oral mucosal
epithelial transplantation, and amniotic membrane (AM)
transplantation.10e12 Penetrating keratoplasty or keratopros-
thesis can be considered after the inflammation has been
controlled.
Graft-versus-host disease (GVHD) is one of the most severe
complications after allogenic hematopoietic stem cell trans-
plantation (HSCT) in patients with mainly hematopoietic
dysfunction or hematologic and lymphoid malignancies.13 In
the pathogenesis of GVHD, it is supposed that grafted cells
attack the recipient's tissues, such as the skin, lungs, liver,
gastrointestinal tract, and eyes. If the intervention of immune-
modulators or steroid therapy is inadequate or delayed, in-
flammatory conjunctiva with or without fibrosis, keratocon-
junctivitis sicca from the destroyed lacrimal gland, and corneal
scarring due to limbal stem cell deficiency (LSCD) will occur.
Some studies demonstrated that cytokines in tear film, such as
interleukin-6 (IL-6) and interferon-gamma (IFN-g), are
strongly correlated to the severity of dry eye in GVHD pa-
tients.14 Thus, anti-inflammatory agents may help in the
treatment of ocular GVHD. Topical cyclosporine has recently
been proposed as an effective agent to control ocular inflam-
mation and dryness in patients with severe dry eyes and
chronic GVHD.15 After stabilization of GVHD treated with
anti-inflammatory agents and frequent lubricants, corneal orlimbal transplantation with reconstruction of the ocular sur-
face are necessary to rescue vision.16
Although the detailed etiology of ocular cicatricial pem-
phigoid (OCP) or mucous membrane pemphigoid remains
unknown, autoantibodies with activated complements are
believed to mediate cytotoxic (type II sensitivity) effects on
the basement membrane and the subsequent breakdown of the
conjunctiva. Some proinflammatory cytokine imbalances have
been detected in patients with OCP, such as elevated macro-
phage migration inhibitory factor and macrophage colony
stimulating factor in tear film,17,18 increasing tumor necrosis
factor-a and decreasing IL-6 levels in serum.19 OCP is clini-
cally characterized to involve the mucous membrane,
including the mouth, oropharynx, kidney, gastroenteric tract,
and genital tract. Based on the severity of OCP, subepithelial
fibrosis (Stage I), loss of goblet cells, fornice shortening (Stage
II), symblepharon (Stage III), and surface keratinization and
extensive adhesion of the lid to the globe (Stage IV) will occur
sequentially. In addition to conventional therapy with topical
steroids and lubricants, biotherapies with interferons, immu-
noglobulins, monoclonal antibodies, rituximab, and myco-
phenolate mofetil are generally investigated.20e22
Erythema multiforme major, the so-called StevenseJohnson
syndrome (SJS), is induced by several medications, including
sulfonamides, anticonvulsants, salicylates, penicillin, ampi-
cillin, and isoniazid; or pathogens such as herpes simplex virus,
mycoplasma, streptococcus, and adenovirus. The pathogenesis
of SJS is the deposition of immune-complex in the dermis and
conjunctival stroma, leading to severe desquamation of the
skin, subepithelial bullae, fibrosis, and scarring of the con-
junctiva. Symblepharon is a severe complication because the
necrotic conjunctivas adhere to each other. The main treatment
for SJS is supportive care using lubricant, ointment, and pro-
phylactic antibiotic drops along with selective steroid admin-
istration to reduce inflammation and protect the cornea and the
conjunctiva from drying out or becoming infected.23 Treatment
outcomes of late sequelae with cicatricial changes and severe
dry eye have been disappointing. Therefore, early topical
treatment in the acute stage is the main goal to reduce the risk of
late complications.24e26
LSCD may result from congenital diseases, such as
congenital aniridia, ectodermal dysplasia, and sclerocornea; or
acquired injuries, including chemical burn, thermal injury,
chronic contact lens wearing, ocular surgery, and chronic
cicatricial conjunctivitis. The re-epithelialization of cornea is
based on the availability of healthy LSCs to renew the corneal
epithelium and, at the same time, to prevent pannus formation
across the cornea from conjunctival vascular intrusion.
Maintaining a healthy corneal surface requires 25e33% intact
limbus; accordingly, transplantation with autologous, allo-
genic, and even cadaveric limbal tissue provides convincing
effects in restoring the corneal surface.27,28
2. The AM and LSCs
The limbus is a unique structure that serves as a barrier
between the cornea and the conjunctiva. Cumulated evidence
214 I.-L. Tsai et al. / Journal of the Chinese Medical Association 78 (2015) 212e217has shown that corneal stem cells reside in the limbal
epithelium and possess characteristics intermediate between
corneal and conjunctival epithelial cells. The stroma of the
LSC niche is full of fibroblasts and melanocytes and is nour-
ished by limbal vasculatures. In the normal corneal renewal
and healing process, the basal cells of the limbal epithelium
may first differentiate into transient amplifying cells with
finite mitotic times and then develop into differentiated cells to
replenish the corneal epithelium.
The AM is the covering layer of the fetus and is composed
of three parts: the epithelium, the basement membrane, and the
stroma. The epithelium monolayer consist of cuboidal cells
which rely on their basal lamina. Evidence shows that several
growth factors, including epidermal growth factor (EGF),
transforming growth factor (TGF)-a, keratinocyte growth
factor, hepatocyte growth factor, fibroblast growth factor,
TGF-b1, and cytokines are present in the epithelial layer of the
amnion.29 The basement membrane serves as a scaffold in all
transplant therapy for epithelial cells to repopulate. The loose
connective tissue of the stroma provides its elasticity. Sup-
pression of TGF-b1 and IL-8 were found in AM-based culture
of corneal, conjunctival, and limbal fibroblasts, providing ev-
idence that the AM has an inhibiting effect on subconjunctival
fibrosis.30 The stromal layer of the AM also possesses vital
anti-inflammatory and anti-angiogenic effects, providing
therapeutic effects when applied to the inflammatory corneal
surface. The clinical effects of the whole AM include
enhanced epithelialization by providing a basement membrane
for cell migration, reinforcing adhesion of basal epithelial
cells, promoting epithelial differentiation, inhibition of
inflammation, neovascularization, and antimicrobial proper-
ties. Thus, the AM may be utilized in repairing corneal and
conjunctival defects, in reconstruction surgery, and in LSC
culture.9,11,12,24,26
Although LSCT provides an option for the treatment of
LSCD, the shortage of donor tissue is still a major issue for
patients with bilateral ocular stem cell deficiency, such as
those with OCP and SJS. The finding that autologous LSCs
could be cultivated and expanded in vitro on the AM suggests
a simple method to repopulate corneal LSCs and considerably
improve the possibility of LSC therapy.31
3. Hydrogels for corneal wound healing
Several types of hydrogels, including collagen, gelatin,
alginate, chitosan, and fibrin, are used at the preclinical and
clinical stages of therapy for corneal regeneration.32 Fibrin
hydrogels are composed of fibrinogen and thrombin, which
have been widely used for various biomedical applications
including drug delivery and tissue engineering.33 Recent
studies showed that fibrin hydrogels provide appropriate mi-
croenvironments to culture LSCs without losing their pheno-
type. Fibrin hydrogels increase the survival rate of LSC and
progenitor cells during the entire culture period.34,35 More-
over, fibrin hydrogels can degrade within 24 hours after
transplantation, which is important for clinical application.34
In a clinical study, patients with corneal damage regaineduseful vision after treatment with LSCs that had been cultured
on fibrin hydrogel.35 Mesenchymal stem cells (MSCs) are
currently being investigated in corneal regeneration. MSCs
can be differentiated into corneal epithelial-like cells in vivo
and ex vivo. In one in vivo study, a rabbit's damaged corneal
surface could be successfully reconstructed by delivery of
MSCs that had been cultured on fibrin hydrogels. The results
suggested that MSCs may participate in the healing process of
injured corneal epithelium.36e38 Collagen is the most abun-
dant protein in the human cornea.39 In cornea regeneration,
collagen hydrogels are mainly used for limbal epithelial cell
(LEC) encapsulation. Collagen hydrogels are biocompatible
and biodegradable and can maintain the proliferation and
differentiation of LECs. However, collagen hydrogels have an
inherently weak structure. Recent studies showed that the gel
strength of collagen can be increased by crosslinking.40e42 In
clinical studies, corneal re-epithelialization occurred in all
patients who had significant vision loss after treatment with a
crosslinked collagen hydrogel.43,44 Gelatin hydrogels have
been used as cell carriers, including corneal endothelial and
stromal cells, and sustained ocular drug release delivery for
cornea regeneration.45e47 An animal study showed that
transplantation of fibroblast precursors combined with gelatin
hydrogel into the corneal stroma may promote cornea wound
healing.47 Alginate is an anionic polysaccharide composed of
1,4-linked b-D-mannuronic acid and its C-5 epimer a-L-
guluronic acid. Alginate hydrogels have found numerous ap-
plications in biomedical engineering, including drug delivery
and tissue engineering, however, only a few studies have been
performed in the field of ophthalmology.48,49 Recent studies
showed that alginate-based hydrogels can be used for LEC and
corneal endothelial cell cultivation. The results suggested that
alginate-based hydrogels may have potential in corneal
regeneration applications.50,51 Chitosan is a linear copolymer
composed of D-glucosamine and N-acetyl-D-glucosamine by
(1,4)-linkage. Chitosan-based biomaterials have been investi-
gated for ocular drug and cell delivery.52e54 A chitosan
membrane has been used to promote wound healing and
decrease scar tissue formation in a rabbit corneal alkali burn
model.55 Chitosan-based hydrogels combined with induced
pluripotent stem cells have been shown to be effective in the
treatment of surgical abrasion-injured corneas in vivo.56
4. Bioengineered prosthetic devices
Corneal transplantation/keratoplasty is a therapeutic inter-
vention used in most patients with corneal blindness. How-
ever, the main problem with corneal transplantation is the
shortage of donor organs.57 Several artificial cornea products,
including osteo-odonto keratoprosthesis (OOKP), AlphaCor,
and Boston keratoprosthesis, have been used clinically in
recent years.57 The Boston type I keratoprosthesis is most
widely used clinically. Patients showed rapid visual recovery
after implantation of the Boston type I keratoprosthesis.58,59
Although synthetic keratoprosthesis provides a treatment
intervention for patients who suffer from corneal blindness,
there still remain some difficulties to overcome for its
Fig. 1. Applications of biomaterials in corneal wound healing.
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corneas have been developed to mimic the corneal architecture
and replace damaged corneas.40,41,60,61 The ideal bio-
engineered cornea should be as similar as possible to native
corneas, including possessing an epithelialized artificial but-
ton, optically functional core, and similar chemical composi-
tion, flexibility, and oxygen permeability.62 Collagen-based
implants have been shown to promote cell and nerve repo-
pulation in a rabbit corneal alkali burn model.60 In a clinical
study, the therapeutic effects of collagen-based implants have
been demonstrated in 10 patients.43 Recently, several novel
biomaterials were developed for corneal tissue engineering.
Recent studies showed that rheological properties of fibrin
with 0.1% agarose are similar to the native cornea.63 The
gelatinechondroitin sulfate scaffold has been used to encap-
sulate rabbit corneal keratocytes for corneal stromal tissue
engineering. The results suggested that the porous structure of
gelatin could provide a suitable nutrient transport to the cells
and showed good biocompatibility in vitro.64 ArgeGlyeAsp
(RGD)-functionalized silk with human cornea fibroblasts have
been studied for corneal tissue engineering. The results
revealed that the RGD-functionalized silk promoted the
attachment, proliferation, and alignment of cells; moreover,
the expression of corneal stroma differentiation markers was
also increased.65
5. Contact lenses and drug delivery
Persistent epithelial defects (PED) of corneas occur when a
damaged area of superficial cornea fails to show re-
epithelialization in the expected time.66 There are several
types of contact lenses that have been developed to treat PED,
including soft, rigid gas-permeable, and scleral contact len-
ses.67 Soft silicone hydrogel contact lenses have higher oxygen
transmission and water content than those of soft conventional
contact lenses, which have gained a lot of attention in recent
years.67,68 The major disadvantage of rigid gas-permeable
contact lenses is the size, which is smaller than that of soft
contact lenses. The mobility of small contact lens on the eye
may increase the risk of abrasions to the cornea, which affect
the healing process of PED.67 Recent studies demonstrated that
scleral contact lens could be beneficial in patients with PED.
Moreover, the scleral contact lens has been used as an alter-
native tarsorrhaphy to manage combined exposure and neuro-
trophic keratopathy.69 Combinations of cells and contact lenses
for ocular surface reconstruction have been studied in patients
with LSCD. Limbal-derived epithelium cultured on silicone
contact lenses displayed a progenitor-like phenotype. The re-
sults of clinical studies showed that re-epithelialization
occurred in all patients after treatment.70,71
In corneal wound healing, there are several approaches for
drug delivery through contact lenses, including soaking,
particle-laden contact lenses, molecular imprinting, and ion
ligands.72 EGF has been encapsulated in hydrogel contact
lenses to treat abraded corneas of rabbits. The results
demonstrated that the overall healing rate in the EGF-treated
contact lenses was significantly higher than in controleyes.73 Hydrogel contact lenses have been used as sustained
release carriers of high-molecular-weight polymer for corneal
wound healing. Hyaluronic acid (HA) was incorporated in
contact lenses through an imprinting method. The results
demonstrated that the hydrogel contact lenses sustained the
release of HA in vitro.74 A recent study showed that vitamin E-
loaded silicone contact lenses can increase the release duration
of hydrophilic drugs; moreover, they can decrease the corneal
damage that results from exposure to UV light.75
In conclusion, to date, the AM is the most widely used
carrier for cell transplantation in corneal wound healing.
However, there are still some limitations with the clinical use
of the AM. In recent years, novel biomaterials have attracted a
great deal of interest in corneal wound healing. Biomaterials
have uniform structures and their physical properties can be
easily modified. Both collagen and fibrin hydrogels have been
used for corneal regeneration in clinical studies. In addition,
gelatin-, alginate-, and chitosan-based hydrogels, bio-
engineered prosthetic devices, and contact lenses are currently
under investigation for corneal regeneration in vitro and
in vivo. We have summarized the recent developments of
biomaterials in this article (Fig. 1). We hope these promising
biomaterials will have great outcomes in treating harmful
ocular surface disorders in the future.
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